← All trials
NCT01405079
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Mar 1, 2017
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 222
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Guangdong Association of Clinical TrialsLead sponsor
- Jilin Provincial Tumor HospitalCollaborator
- Qingdao UniversityCollaborator
- Fudan UniversityCollaborator
- Zhejiang UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Shantou UniversityCollaborator
- Sichuan UniversityCollaborator
- Capital Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Shantou UniversityStudy director
- People's Liberation Army of ChinaCollaborator
- Shantou UniversityOverall official - principal investigator
- Tsinghua UniversityCollaborator
- Peking UniversityCollaborator
- Soochow UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Guangdong Association of Clinical TrialsReponsible party - principal investigator
- Shantou UniversityStudy chair
- China Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.